Document › Details
Centogene AG. (6/1/14). "Presss Release: Centogene CEO Position Changed – Michael Schlenk Hands Over to Founder Prof Arndt Rolfs". Rostock.
|Organisation 2||Curasan AG|
|Product 2||genetic test|
|Index term 2||Centogene–OMERS (CA): investment, 201402 acquisition of Centogene’s Canadian business by LifeLabs|
|Person||Rolfs, Arndt (Univ Rostock Prof + Centogene 201406– CEO + Founder)|
|Person 2||Schlenk, Michael (Curasan 201410– Executive Board Director before Centogene + ProBioGen)|
After 3.5 years as Chief Executive Officer for Centogene and the successful completion of a 2-digit million deal with LifeLabs, the largest clinical-diagnostic laboratory in Canada, Michael Schlenk transfers the responsibilities as CEO to Prof. Arndt Rolfs MD.
Schlenk will continue to support the company as an active member of the supervisory board.
Over the last few years Centogene, an always profitable, completely venture capital free and rapidly growing company in the North of Germany, increased turnover and number of employees 4 fold. Today, Centogene is one of the leading molecular genetic diagnostic companies worldwide, specializing in rare diseases. With the broadest portfolio of over 2000 genetic tests, whole-exome and whole-genome platform as well as mass-spectrometry unit Centogene is a one-stop-shop for many of its customers from over 90 countries.
“With the capital from the Canadian partnership deal, we have the funds to further invest in technological expansion and automation. We will aggressively expand our Next Generation Sequencing leadership with over 150 specific and highly validated panels, the robots processing industry screening projects and the centerpiece of our business model, the CentoMD0174 Mutation Databse,” explains Michael Schlenk. “We are very fortunate that we could win the internationally reputated expert in genetics, our founder and visionary leader in genetics, Prof. Rolfs, to drive the technological expansion and raise Centogene to the next level as the new Chief Executive Officer.”
“Michael Schlenk will continue to support us with his network and strategic understanding as an active member of the supervisory board. We thank him for his substantial contributions in closing several very important business deals as a basis for further growth of Centogene,” said Prof. Arndt Rolfs, new CEO of Centogene AG.
Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders, offering mor than 2,000 routine genetic and biochemical tests. In addition the team performs the development of innovative biomarkers for lysosomal storage disorders and small molecules for the treatment of rare diseases. Centogene works with academic and industrial partners to co-develop cutting-edge diagnostic techniques and new orphan drugs.
For more information, please visit www.centogene.com
About Michael Schlenk
After over 20 years as senior executive, general manager and president in Pharma companies like Sandoz/Novartis and Abbott, Schlenk worked successfully in Biotech for over 10 years as CEO. As business angel, he invests in Life Science, but also IT companies and helps young organizations to develop their business model to stability and value creation.
About Arndt Rolfs
Arndt Rolfs, Professor for Neurology and Psychiatry at the University of Rostok, Germany and head of the Albrecht-Kossel-Institute for Neuroregeneration works for over 25 years in the field of clinical neurology and neurogenetic research. He is principal investigator of several international multicentre studies in the area of rare diseases. Rolfs has authored and contributed to more than 150 peer-reviewed publications, acts as a consultant for international biotech and industrial companies as well as for the EMA and FDA.
Furthermore, he was co-founder of biotech companies Arcensus AG and Genebanking AG.
Record changed: 2016-06-07
More documents for Centogene (Group)
-  Centogene AG. (9/16/15). "Press Release: Prof. Peter Bauer as New Member in the Management Board at Centogene"....
-  LifeLabs Medical Laboratory Services. (2/19/14). "Presss Release: LifeLabs Medical Laboratory Services Acquires Centogene’s Canadian Business". Toronto, ON....
-  BIOPRO Baden-Württemberg GmbH. (4/15/13). "News: Molecule-specific Diagnosis of Metabolic Diseases"....
-  Centogene Holding AG. (1/18/11). "Press Release: Michael Schlenk New Chief Executive Officer of Centogene Holding AG". Freiburg....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to email@example.com and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)